Testing a new treatment for children with a serious kidney condition
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new medicine called INM004 in children with STEC-HUS, a serious illness that damages the kidneys and blood cells. It may help speed up recovery and prevent complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (your child) are 9 months to 17 years old.
- You are hospitalized with confirmed STEC infection and have signs of kidney damage, anemia, and low platelets.
- Symptoms started within 10 days before being diagnosed with STEC-HUS.
- You have not started dialysis in the last 48 hours or been diagnosed with STEC-HUS more than 24 hours ago.
- You have no history of chronic kidney problems, atypical HUS, or severe allergies to horse-based medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving extra (hyper) fluids early helps children with a high-risk E. coli stomach infection. The goal is to improve outcomes by supporting the kidneys during the illness.
This trial tests a new medicine for people with a rare blood disorder called atypical hemolytic uremic syndrome (aHUS) that is still active despite other treatments. The drug aims to stop the ongoing damage to blood cells and kidneys.
This study looks at how rare gene mutations may explain atypical HUS (aHUS) and how that could guide more personalized treatment. It mainly involves people who have had aHUS affecting blood counts and kidneys.
This trial studies eculizumab, a targeted blood-clotting and immune system medicine, for adults hospitalized with hypertensive emergency–associated hemolytic uremic syndrome (a serious condition affecting kidneys and blood). It aims to see whether the drug can improve outcomes after this life-threatening event.
This trial looks at whether a blood-filter treatment (called “AN69ST Verse PS” using a hemofilter) can help children with early, serious sepsis and poor circulation or organ problems. It may help stabilize the body faster, but eligibility is limited to certain sepsis situations and recent timing.
This study measures how certain medicines move through the body and checks their safety in children. It may help doctors better understand dosing and side effects in kids who are already receiving these treatments, or in some kids who recently tested positive for COVID-19.
Hear when a new Hemolytic-Uremic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.